What is CereVasc?
CereVasc, Inc. is dedicated to pioneering minimally invasive therapeutic solutions for neurological conditions, with a primary focus on communicating hydrocephalus. The company is actively developing its eShunt System, a novel device designed to enhance patient outcomes and reduce the economic burden associated with conventional neurosurgical interventions for this prevalent neurological disorder affecting both pediatric and adult populations. CereVasc's core mission revolves around advancing the field of cerebrospinal fluid management and therapy through technological innovation.
How much funding has CereVasc raised?
CereVasc has raised a total of $113.9M across 2 funding rounds:
Series A
$43.9M
Series B
$70M
Series A (2020): $43.9M with participation from ATON Partners LLC and Perceptive Xontogeny Venture Fund
Series B (2024): $70M led by Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund
Key Investors in CereVasc
Bain Capital Life Sciences
Bain Capital Life Sciences is a prominent venture capital firm known for its strategic investments in the healthcare and life sciences sectors, likely focusing on companies with innovative therapeutic technologies.
Perceptive Xontogeny Venture Fund
Perceptive Xontogeny Venture Fund is an investment entity that typically backs early-stage and growth-stage companies within the biotechnology and medical device industries, seeking to drive advancements in healthcare.
ATON Partners LLC
ATON Partners LLC is an investment firm that provides capital for companies, often with a focus on strategic growth and development within various industries, including potentially medical devices.
What's next for CereVasc?
The substantial enterprise-level funding, including the recent major strategic investment, positions CereVasc for accelerated development and market penetration. This capital infusion is expected to fuel the advancement of the eShunt System through clinical trials and regulatory approvals, ultimately enabling the company to scale its operations and commercialize its groundbreaking technology. The company's trajectory suggests a focus on expanding its footprint in the neurosurgical device market and solidifying its leadership in cerebrospinal fluid management solutions.
See full CereVasc company page
